Abstract
We estimated the population-level incidence of human papillomavirus (HPV)-positive oropharyngeal, cervical, and anal cancers by smoking status. We combined HPV DNA genotyping data from the Centers for Disease Control and Prevention's Cancer Registry Sentinel Surveillance System with data from the Kentucky Cancer Registry and Behavioral Risk Factor Surveillance System across smoking status. During 2004-2005 and 2014-2015 in Kentucky, most cases of oropharyngeal (63.3%), anal (59.7%), and cervical (54.9%) cancer were among individuals who ever smoked. The population-level incidence rate was higher among individuals who ever smoked than among those who never smoked for HPV-positive oropharyngeal (7.8 vs 2.1; adjusted incidence rate ratio = 2.6), cervical (13.7 vs 6.8; adjusted incidence rate ratio = 2.0), and anal (3.9 vs 1.6; adjusted incidence rate ratio = 2.5) cancers. These findings indicate that smoking is associated with increased risk of HPV-positive oropharyngeal, cervical, and anal cancers, and the population-level burden of these cancers is higher among individuals who ever smoked.
| Original language | English |
|---|---|
| Pages (from-to) | 1173-1177 |
| Number of pages | 5 |
| Journal | Journal of the National Cancer Institute |
| Volume | 116 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2024 |
Bibliographical note
Publisher Copyright:© 2024 Published by Oxford University Press.
Funding
This project was supported in part by an appointment (S.V.G. and J.M.M.) to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. This project was supported in part by an appointment (S.V.G. and J.M.M.) to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC and the National Institutes of Health. The authors are grateful for the efforts of cancer registry coordinators as well as BRFSS coordinators and survey participants. Results in this manuscript were presented in part as a poster presentation at the International Papillomavirus Conference in April 2023.
| Funders | Funder number |
|---|---|
| Oak Ridge Institute for Science and Education | |
| U.S. Department of Energy EPSCoR | |
| Centers for Disease Control and Prevention | |
| National Institutes of Health (NIH) |
ASJC Scopus subject areas
- Oncology
- Cancer Research
